輝瑞公司;COVX TECHNOLOGIES IRELAND LIMITED;科技愛爾蘭有限公司;PFIZER INC.
发明人:
ANNATHUR, Gopinath Vedachalam GV,BALU, Palani P,FINN, Rory Francis RF,HUANG, Jie J,LAURENT, Olivier Alexandre OA,LEVIN, Nancy Jane,NJ,LUKSHA, Nicholas Gary NG,MARTIN, Joseph Patrick Jr JP,MOSKOWITZ, H,‧安納圖爾,‧巴盧,‧芬恩,‧黃,‧勞倫特,‧萊溫,‧盧克沙,‧小馬丁,MARTIN,
申请号：
HK15101306.0
公开号：
HK1200726A
申请日:
2015.02.05
申请国别(地区):
HK
年份:
2015
代理人:
摘要：
The present invention provides a composition of the formula: [FGF21-1st Linker]-[Ab]-[2nd-Linker-Ex4]； wherein FGF21 is an FGF21 homologue； and Ex4 is an Exendin4 homologue； and Ab is an aldolase catalytic antibody or antigen binding portion thereof； and the 1st linker is covalently attached to the side chain of a protein-linking residue in FGF21 and to a combining site of the antibody, and the 2nd linker is covalently attached to the side chain of a peptide-linking residue in Ex4 and to a combining site of the antibody, and wherein the first and second linker are the same or different. Various uses of the compounds are provided, including methods to prevent or treat diabetes or diabetes-related conditions.
